Lauren J Rice1, Stewart L Einfeld1, Nan Hu2, C Sue Carter3. 1. The Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia. 2. Centre for Developmental Psychiatry & Psychology, Department of Psychiatry, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia. 3. Kinsey Institute and Department of Biology, Indiana University Bloomington, United States.
Abstract
PURPOSE OF REVIEW: PWS is a severe developmental disability for which there is no known treatment. The oxytocin system is currently a primary target for intervention. The aim of this article is to review the evidence for the efficacy of intranasal oxytocin in PWS. RECENT FINDINGS: To date, there have been five clinical trials of oxytocin in PWS. Four of these studies reported that oxytocin improved behaviors. However, each of these studies suffered important limitations that likely influenced the findings. For example, one study did not include a control group. Another study did not statistically analyze the effects of oxytocin on behavior. The final two studies used study-specific measures for which psychometric properties have not been assessed. SUMMARY: Because of these limitations, the most appropriate conclusion to draw from the existing studies is that there is currently no convincing evidence that intranasal oxytocin improves symptoms of PWS. However, this does not mean that oxytocin is not involved in PWS. Rather, it suggests that further work is needed to understand the nature of the PWS oxytocin abnormality.
PURPOSE OF REVIEW: PWS is a severe developmental disability for which there is no known treatment. The oxytocin system is currently a primary target for intervention. The aim of this article is to review the evidence for the efficacy of intranasal oxytocin in PWS. RECENT FINDINGS: To date, there have been five clinical trials of oxytocin in PWS. Four of these studies reported that oxytocin improved behaviors. However, each of these studies suffered important limitations that likely influenced the findings. For example, one study did not include a control group. Another study did not statistically analyze the effects of oxytocin on behavior. The final two studies used study-specific measures for which psychometric properties have not been assessed. SUMMARY: Because of these limitations, the most appropriate conclusion to draw from the existing studies is that there is currently no convincing evidence that intranasal oxytocin improves symptoms of PWS. However, this does not mean that oxytocin is not involved in PWS. Rather, it suggests that further work is needed to understand the nature of the PWSoxytocin abnormality.
Authors: Maéva Langouët; Dea Gorka; Clarisse Orniacki; Clémence M Dupont-Thibert; Michael S Chung; Heather R Glatt-Deeley; Noelle Germain; Leann J Crandall; Justin L Cotney; Christopher E Stoddard; Marc Lalande; Stormy J Chamberlain Journal: Hum Mol Genet Date: 2020-11-25 Impact factor: 6.150
Authors: David E Godler; Ling Ling; Dinusha Gamage; Emma K Baker; Minh Bui; Michael J Field; Carolyn Rogers; Merlin G Butler; Alessandra Murgia; Emanuela Leonardi; Roberta Polli; Charles E Schwartz; Cindy D Skinner; Angelica M Alliende; Lorena Santa Maria; James Pitt; Ronda Greaves; David Francis; Ralph Oertel; Min Wang; Cas Simons; David J Amor Journal: JAMA Netw Open Date: 2022-01-04
Authors: D A Martins; N Mazibuko; F Zelaya; S Vasilakopoulou; J Loveridge; A Oates; S Maltezos; M Mehta; S Wastling; M Howard; G McAlonan; D Murphy; S C R Williams; A Fotopoulou; U Schuschnig; Y Paloyelis Journal: Nat Commun Date: 2020-03-03 Impact factor: 14.919